Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Former Division Of Nonprescription Clinical Evaluation Head Leonard-Segal Talks About OTC Switches Past, Present And Future

This article was originally published in The Pink Sheet Daily

Executive Summary

Andrea Leonard-Segal and Melissa Furness talked with “The Tan Sheet” about the evolving opportunities for Rx-to-OTC switch and the significance of recent switches. Leonard-Segal, the former director of FDA’s Division of Nonprescription Clinical Evaluation, and Furness, a former DNCE supervisory consumer safety officer, started a consultancy to offer guidance on OTC switch programs and other regulatory areas.

Advertisement

Related Content

Plan B One-Step OTC Proposal Leaves Plaintiffs, Judge Korman Wary
FDA’s Broad Power Can Overcome NSURE Labeling Obstacles – Attorney
Sponsors Should Hang Tight On “New Paradigm” Switch – CDER’s Leonard-Segal
FDA Evaluates Alli For Potential Serious Risk Of Kidney Stones
Label Comprehension Guidance May Improve Switch Outlook
FDA's ONP Reorganization Challenges Industry To Prioritize OTCs
DNCE Could Improve NDA Process With More Staffing, Sponsor Meetings
NDAC Panelists Look At Future Of Behavior Research For OTC Postmarket
Actual Use, Label Comprehension Guidances Slated For 2006

Topics

Advertisement
UsernamePublicRestriction

Register

PS075942

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel